Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Rheumatic Heart Disease I: Introduction

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Novel Perspective on a Genetically Altered Model of SARS-CoV-2 Myocarditis: The LDLR-OPN Axis.

JACC. Basic to translational science·2026

Same author

Current state of knowledge on the epidemiology, aetiology, diagnosis, and management of heart involvement in eosinophilia. A Clinical Consensus Statement of the ESC Working Group on Myocardial & Pericardial Diseases.

European journal of heart failure·2026

Same author

Time-Critical Cardiovascular Risk After COVID-19: A Population-Based Analysis Across Variant Eras.

Mayo Clinic proceedings. Innovations, quality & outcomes·2026

Same author

A Pragmatic Approach to Acute Myocarditis in the Era of Advanced Diagnostics: From Diagnostic Certainty to Risk-Based Care.

Journal of cardiac failure·2026

Same author

Navigating the Spectrum of Inflammatory Myocardial and Pericardial Syndromes: A Contemporary Approach to Diagnosis and Management.

Journal of cardiac failure·2026

Same author

Corrigendum to 'The Mechanism and Natural History of Mitral Regurgitation in Cardiac Sarcoidosis' [The American Journal of Cardiology 191 (2023) 84-91].

The American journal of cardiology·2026

Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026

Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026

Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026

Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026

Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026

Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026

See all related articles

Search research articles

Related Experiment Videos

Cardiac sarcoidosis.

Jessica S Kim¹, Marc A Judson, Robert Donnino

¹New York University School of Medicine, New York, NY 10016, USA. jessica.kim@med.nyu.edu

American Heart Journal

|December 17, 2008

Summary

This summary is machine-generated.

Cardiac sarcoidosis (CS) is a serious heart condition that can cause sudden death. Early screening and treatment are vital for all sarcoidosis patients to prevent life-threatening complications.

Related Experiment Videos

Area of Science:

Cardiology
Immunology

Background:

Cardiac sarcoidosis (CS) is a rare, potentially fatal condition.
Clinical manifestations range from heart failure to sudden death.
Asymptomatic cardiac involvement is more common than previously recognized.

Purpose of the Study:

To highlight the prevalence and risks of cardiac sarcoidosis.
To emphasize the need for screening all sarcoidosis patients for cardiac involvement.
To discuss current diagnostic and therapeutic challenges.

Main Methods:

Review of current literature and clinical observations.
Discussion of diagnostic advancements, particularly in imaging.
Analysis of treatment strategies and the need for standardization.

Main Results:

Minimally symptomatic or asymptomatic CS is highly prevalent.
Patients with CS, even without symptoms, are at risk for sudden cardiac death.
Implantable cardioverter-defibrillators may be indicated for both symptomatic and asymptomatic patients.

Conclusions:

All sarcoidosis patients require screening for cardiac involvement.
Aggressive workup and potential implantable cardioverter-defibrillator therapy are crucial for symptomatic CS.
Further randomized clinical trials are essential to standardize CS therapy, especially for asymptomatic cases.